[go: up one dir, main page]

AR119138A1 - Moduladores de cot y métodos de uso de los mismos - Google Patents

Moduladores de cot y métodos de uso de los mismos

Info

Publication number
AR119138A1
AR119138A1 ARP200101649A ARP200101649A AR119138A1 AR 119138 A1 AR119138 A1 AR 119138A1 AR P200101649 A ARP200101649 A AR P200101649A AR P200101649 A ARP200101649 A AR P200101649A AR 119138 A1 AR119138 A1 AR 119138A1
Authority
AR
Argentina
Prior art keywords
alkyl
heterocyclyl
heteroaryl
cycloalkyl
aryl
Prior art date
Application number
ARP200101649A
Other languages
English (en)
Inventor
Eda Y Canales
Manoj C Desai
Eric M Gorman
Jiayao Li
Roland D Saito
James G Taylor
Nathan E Wright
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of AR119138A1 publication Critical patent/AR119138A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)

Abstract

Reivindicación 1: Un compuesto de la fórmula (1) en donde R¹ es hidrógeno, -O-R⁷, -N(R⁸)(R⁹), -C(O)-R⁷, -S(O)₂-R⁷, alquilo -C₁₋₉, alquenilo C₂₋₆, alquinilo C₂₋₆, cicloalquilo C₃₋₁₅, heterociclilo, arilo, o heteroarilo; en donde cada alquilo C₁₋₉, alquenilo C₂₋₆, alquinilo C₂₋₆, cicloalquilo C₃₋₁₅, heterociclilo, arilo, y heteroarilo puede ser opcionalmente sustituido con uno a cuatro Z¹; R² es hidrógeno, -C(O)-R⁷, -C(O)O-R⁷, -C(O)N(R⁷)₂, alquilo C₁₋₉, alquenilo C₂₋₆, alquinilo C₂₋₆, haloalquilo C₁₋₆, cicloalquilo C₃₋₁₅, arilo, heterociclilo, o heteroarilo; en donde cada alquilo C₁₋₉, alquenilo C₂₋₆, alquinilo C₂₋₆, haloalquilo C₁₋₆, cicloalquilo C₃₋₁₅, arilo, heterociclilo, y heteroarilo puede ser opcionalmente sustituido con uno a cuatro Z²; o R¹ y R² junto con el nitrógeno al cual están unidos para formar un heterociclilo o heteroarilo, en donde cada heterociclilo o heteroarilo es opcionalmente sustituido con uno a cuatro Z²; R³ es heterociclilo o heteroarilo, en donde cada heterociclilo o heteroarilo es opcionalmente sustituido con uno a cuatro Z³; R⁴ es arilo, heterociclilo o heteroarilo, en donde cada arilo, heterociclilo, o heteroarilo es opcionalmente sustituido con uno a cuatro Z⁴; R⁵ es hidrógeno, halo, -CN, -NO₂, -O-R⁷, -N(R⁸)(R⁹), -S(O)-R⁷, -S(O)₂R⁷, -S(O)₂N(R⁷)₂, -C(O)R⁷, -OC(O)-R⁷, -C(O)O-R⁷, -OC(O)O-R⁷, -OC(O)N(R¹⁰)(R¹¹), -C(O)N(R⁷)₂, -N(R⁷)C(O)(R⁷), alquilo C₁₋₉, alquenilo C₂₋₆, alquinilo C₂₋₆, alquilotio C₁₋₉, haloalquilo C₁₋₆, cicloalquilo C₃₋₁₅, arilo, heterociclilo, o heteroarilo; en donde cada alquilo C₁₋₉, alquenilo C₂₋₆, alquinilo C₂₋₆, alquilotio C₁₋₉, haloalquilo C₁₋₆, cicloalquilo C₃₋₁₅, arilo, heterociclilo, y heteroarilo puede ser opcionalmente sustituido con uno a cuatro Z⁵; R⁶ es -C(O)O-R¹⁶-OP(O)(OR¹²)₂, -C(O)-R¹⁶-OP(O)(OR¹²)₂, -R¹⁶-OP(O)(OR¹²)₂, -C(O)O-R¹⁶-OR¹⁷; -C(O)O-R¹⁶-OH; -C(O)O-R¹⁶-OC(O)R¹⁷; -C(O)-C(O)OR¹², o -C(O)O-R¹⁶-OC(O)R¹⁷NH₂; cada R⁷ es independientemente hidrógeno, C₁₋₉ alquilo, C₂₋₆ alquenilo, C₂₋₆ alquinilo, C₁₋₆ haloalquilo, C₃₋₁₅ cicloalquilo, arilo, heterociclilo, o heteroarilo; en donde cada C₁₋₉ alquilo, C₂₋₆ alquenilo, C₂₋₆ alquinilo, C₁₋₆ haloalquilo, C₃₋₁₅ cicloalquilo, arilo, heterociclilo, y heteroarilo puede ser opcionalmente sustituido con uno a cuatro Z⁷; R⁸ y R⁹ en cada caso son independientemente hidrógeno, -S(O)₂R¹⁰, -C(O)-R¹⁰, -C(O)OR¹⁰, -C(O)N(R¹⁰)(R¹¹), alquilo C₁₋₉, alquenilo C₂₋₆, alquinilo C₂₋₆, haloalquilo C₁₋₆, cicloalquilo C₃₋₁₅, arilo, heterociclilo, o heteroarilo; en donde cada alquilo C₁₋₉, alquenilo C₂₋₆, alquinilo C₂₋₆, haloalquilo C₁₋₆, cicloalquilo C₃₋₁₅, arilo, heterociclilo, o heteroarilo puede ser opcionalmente sustituido con uno a cuatro Z⁸; R¹⁰ y R¹¹ en cada caso son independientemente hidrógeno, alquilo C₁₋₉, alquenilo C₂₋₆, alquinilo C₂₋₆, haloalquilo C₁₋₆, cicloalquilo C₃₋₁₅, arilo, heterociclilo, o heteroarilo, en donde cada alquilo C₁₋₉, alquenilo C₂₋₆, alquinilo C₂₋₆, haloalquilo C₁₋₆, cicloalquilo C₃₋₁₅, arilo, heterociclilo, y heteroarilo opcionalmente es sustituido con uno a cuatro Z¹ᵇ; cada Z¹, Z², Z³, Z⁴, Z⁵, Z⁶, Z⁷, y Z⁸ es independientemente hidrógeno, oxo, halo, -NO₂, -N₃, -CN, tioxo, C₁₋₉ alquilo, C₂₋₆ alquenilo, C₂₋₆ alquinilo, C₃₋₁₅ cicloalquilo, C₁₋₈ haloalquilo, arilo, heteroarilo, heterociclilo, -O-R¹², -C(O)-R¹², -C(O)O-R¹², -C(O)-N(R¹³)(R¹⁴), -N(R¹³)(R¹⁴), -N(R¹³)₂(R¹⁴)⁺, -N(R¹²)C(O)-R¹², -N(R¹²)C(O)O-R¹², -N(R¹²)C(O)N(R¹³)(R¹⁴), -N(R¹²)S(O)₂(R¹²), -NR¹²S(O)₂N(R¹³)(R¹⁴), -NR¹²S(O)₂O(R¹²), -OC(O)R¹², -OC(O)-N(R¹³)(R¹⁴), -P(O)(OR¹²)₂, -OP(O)(OR¹²)₂, -CH₂P(O)(OR¹²)₂, -OCH₂P(O)(OR¹²)₂, -C(O)OCH₂P(O)(OR¹²)₂, -P(O)(R¹²)(OR¹²), -OP(O)(R¹²)(OR¹²), -CH₂P(O)(R¹²)(OR¹²), -OCH₂P(O)(R¹²)(OR¹²), -C(O)OCH₂P(O)(R¹²)(OR¹²), -P(O)(N(R¹²)₂)₂, -OP(O)(N(R¹²)₂)₂, -CH₂P(O)(N(R¹²)₂)₂, -OCH₂P(O)(N(R¹²)₂)₂, -C(O)OCH₂P(O)(N(R¹²)₂)₂, -P(O)(N(R¹²)₂)(OR¹²), -OP(O)(N(R¹²)₂)(OR¹²), -CH₂P(O)(N(R¹²)₂)(OR¹²), -OCH₂P(O)(N(R¹²)₂)(OR¹²), -C(O)OCH₂P(O)(N(R¹²)₂)(OR¹²), -P(O)(R¹²)(N(R¹²)₂), -OP(O)(R¹²)(N(R¹²)₂), -CH₂P(O)(R¹²)(N(R¹²)₂), -OCH₂P(O)(R¹²)(N(R¹²)₂), -C(O)OCH₂P(O)(R¹²)(N(R¹²)₂), -Si(R¹²)₃, -S-R¹², -S(O)R¹², -S(O)(NH)R¹², -S(O)₂R¹² o -S(O)₂N(R¹³)(R¹⁴); en donde cualquier alquilo, alquenilo, alquinilo, cicloalquilo, haloalquilo, arilo, heteroarilo o heterociclilo es opcionalmente sustituido con uno a cuatro grupos Z¹ᵃ; cada Z¹ᵃ es independientemente oxo, halo, tioxo, -NO₂, -CN, -N₃, C₁₋₉ alquilo, C₂₋₆ alquenilo, C₂₋₆ alquinilo, C₃₋₁₅ cicloalquilo, C₁₋₈ haloalquilo, arilo, heteroarilo, heterociclilo, -OR¹², -C(O)R¹², -C(O)O-R¹², -C(O)N(R¹³)(R¹⁴), -N(R¹³)(R¹⁴), -N(R¹³)₂(R¹⁴)⁺, -N(R¹²)-C(O)R¹², -N(R¹²)C(O)O(R¹²), -N(R¹²)C(O)N(R¹³)(R¹⁴), -N(R¹²)S(O)₂(R¹²), -N(R¹²)S(O)₂-N(R¹³)(R¹⁴), -N(R¹²)S(O)₂O(R¹²), -OC(O)R¹², -OC(O)OR¹², -OC(O)-N(R¹³)(R¹⁴), -Si(R¹²)₃, -S-R¹², -S(O)R¹², -S(O)(NH)R¹², -S(O)₂R¹² o -S(O)₂N(R¹³)(R¹⁴); en donde cualquier alquilo, alquenilo, alquinilo, cicloalquilo, arilo, heteroarilo o heterociclilo es opcionalmente sustituido con uno a cuatro grupos Z¹ᵇ; cada R¹² es independientemente hidrógeno, C₁₋₉ alquilo, C₂₋₆ alquenilo, C₂₋₆ alquinilo, C₃₋₁₅ cicloalquilo, arilo, heteroarilo o heterociclilo, en donde cualquier alquilo, alquenilo, alquinilo, cicloalquilo, arilo, heteroarilo o heterociclilo es opcionalmente sustituido con uno a cuatro grupos Z¹ᵇ; R¹³ y R¹⁴ en cada caso son cada independientemente hidrógeno, C₁₋₉ alquilo, C₂₋₆ alquenilo, C₂₋₆ alquinilo, C₃₋₁₅ cicloalquilo, arilo, heteroarilo o heterociclilo; en donde cualquier alquilo, alquenilo, alquinilo, cicloalquilo, arilo, heteroarilo o heterociclilo es opcionalmente sustituido con uno a cuatro Z¹ᵇ grupos, o R¹³ y R¹⁴ junto con el nitrógeno al cual ellos se unen para formar un heterociclilo, en donde dicho heterociclilo es opcionalmente sustituido con uno a cuatro grupos Z¹ᵇ; cada R¹⁵ es independientemente halo, -CN, -NO₂, -O-R⁷, -N(R⁸)(R⁹), -S(O)-R⁷, -S(O)₂R⁷, -S(O)₂N(R⁷)₂, -C(O)R⁷, -OC(O)-R⁷, -C(O)O-R⁷, -OC(O)O-R⁷, -OC(O)N(R¹⁰)(R¹¹), -C(O)N(R⁷)₂, -N(R⁷)C(O)(R⁷), C₁₋₉ alquilo, C₂₋₆ alquenilo, C₂₋₆ alquinilo, C₁₋₉ alquilotio, C₁₋₆ haloalquilo, C₃₋₁₅ cicloalquilo, arilo, heterociclilo, o heteroarilo; R¹⁶ es -C₁₋₃ alquilo o ciclopropil opcionalmente sustituido con uno a cuatro C₁₋₃ alquilo o ciclopropil; R¹⁷ es C₁₋₉ alquilo, cicloalquilo, o heterociclilo opcionalmente sustituido con uno a tres R¹⁶; y cada Z¹, Z², Z⁴, Z⁵, Z⁷, y Z⁸ es independientemente hidrógeno, oxo, halo, -NO₂, -N₃, -CN, tioxo, C₁₋₉ alquilo, C₂₋₆ alquenilo, C₂₋₆ alquinilo, C₃₋₁₅ cicloalquilo, C₁₋₈ haloalquilo, arilo, heteroarilo, heterociclilo, -O-R¹², -C(O)-R¹², -C(O)O-R¹², -C(O)-N(R¹³)(R¹⁴), -N(R¹³)(R¹⁴), -N(R¹³)₂(R¹⁴)⁺, -N(R¹²)C(O)-R¹², -N(R¹²)C(O)O-R¹², -N(R¹²)C(O)N(R¹³)(R¹⁴), -N(R¹²)S(O)₂(R¹²), -NR¹²S(O)₂N(R¹³)(R¹⁴), -NR¹²S(O)₂O(R¹²), -OC(O)R¹², -OC(O)-N(R¹³)(R¹⁴), -P(O)(OR¹²)₂, -OP(O)(OR¹²)₂, -CH₂P(O)(OR¹²)₂, -OCH₂P(O)(OR¹²)₂, -C(O)OCH₂P(O)(OR¹²)₂, -P(O)(R¹²)(OR¹²), -OP(O)(R¹²)(OR¹²), -CH₂P(O)(R¹²)(OR¹²), -OCH₂P(O)(R¹²)(OR¹²), -C(O)OCH₂P(O)(R¹²)(OR¹²), -P(O)(N(R¹²)₂)₂, -OP(O)(N(R¹²)₂)₂, -CH₂P(O)(N(R¹²)₂)₂, -OCH₂P(O)(N(R¹²)₂)₂, -C(O)OCH₂P(O)(N(R¹²)₂)₂, -P(O)(N(R¹²)₂)(OR¹²), -OP(O)(N(R¹²)₂)(OR¹²), -CH₂P(O)(N(R¹²)₂)(OR¹²), -OCH₂P(O)(N(R¹²)₂)(OR¹²), -C(O)OCH₂P(O)(N(R¹²)₂)(OR¹²), -P(O)(R¹²)(N(R¹²)₂), -OP(O)(R¹²)(N(R¹²)₂), -CH₂P(O)(R¹²)(N(R¹²)₂), -OCH₂P(O)(R¹²)(N(R¹²)₂), -C(O)OCH₂P(O)(R¹²)(N(R¹²)₂), -Si(R¹²)₃, -S-R¹², -S(O)R¹², -S(O)(NH)R¹², -S(O)₂R¹² o -S(O)₂N(R¹³)(R¹⁴); en donde cualquier alquilo, alquenilo, alquinilo, cicloalquilo, haloalquilo, arilo, heteroarilo o heterociclilo es opcionalmente sustituido con uno a cuatro grupos Z¹ᵃ; Z⁹ es hidrógeno, halo, -CN, o -O-R¹²; cada Z¹ᵃ es independientemente oxo, halo, tioxo, -NO₂, -CN, -N₃, C₁₋₉ alquilo, C₂₋₆ alquenilo, C₂₋₆ alquinilo, C₃₋₁₅ cicloalquilo, C₁₋₈ haloalquilo, arilo, heteroarilo, heterociclilo, -O-R¹², -C(O)R¹², -C(O)O-R¹², -C(O)N(R¹³)(R¹⁴), -N(R¹³)(R¹⁴), -N(R¹³)₂(R¹⁴)⁺, -N(R¹²)-C(O)R¹², -N(R¹²)C(O)O(R¹²), -N(R¹²)C(O)N(R¹³)(R¹⁴), -N(R¹²)S(O)₂(R¹²), -N(R¹²)S(O)₂-N(R¹³)(R¹⁴), -N(R¹²)S(O)₂O(R¹²), -OC(O)R¹², -OC(O)OR¹², -OC(O)-N(R¹³)(R¹⁴), -Si(R¹²)₃, -S-R¹², -S(O)R¹², -S(O)(NH)R¹², -S(O)₂R¹² o -S(O)₂N(R¹³)(R¹⁴); en donde cualquier alquilo, alquenilo, alquinilo, cicloalquilo, arilo, heteroarilo o heterociclilo es opcionalmente sustituido con uno a cuatro grupos Z¹ᵇ; cada Z¹ᵇ es independientemente oxo, tioxo, hidroxi, halo, -NO₂, -N₃, -CN, C₁₋₉ alquilo, C₂₋₆ alquenilo, C₂₋₆ alquinilo, C₃₋₁₅ cicloalquilo, C₁₋₈ haloalquilo, arilo, heteroarilo, heterociclilo, -O(C₁₋₉ alquilo), -O(C₂₋₆ alquenilo), -O(C₂₋₆ alquinilo), -O(C₃₋₁₅ cicloalquilo), -O(C₁₋₈ haloalquilo), -O(arilo), -O(heteroarilo), -O(heterociclilo), -NH₂, -NH(C₁₋₉alquilo), -NH(C₂₋₆ alquenilo), -NH(C₂₋₆ alquinilo), -NH(C₃₋₁₅ cicloalquilo), -NH(C₁₋₈ haloalquilo), -NH(arilo), -NH(heteroarilo), -NH(heterociclilo), -N(C₁₋₉ alquilo)₂, -N(C₂₋₆ alquenilo)₂, -N(C₂₋₆ alquinilo)₂, -N(C₃₋₁₅ cicloalquilo)₂, -N(C₁₋₈ haloalquilo)₂, -N(arilo)₂, -N(heteroarilo)₂, -N(heterociclilo)₂, -N(C₁₋₉ alquilo)(C₂₋₆ alquenilo), -N(C₁₋₉ alquilo)(C₂₋₆ alquinilo), -N(C₁₋₉ alquilo)(C₃₋₁₅ cicloalquilo), -N(C₁₋₉ alquilo)(C₁₋₈ haloalquilo), -N(C₁₋₉ alquilo)(arilo), -N(C₁₋₉ alquilo)(heteroarilo), -N(C₁₋₉ alquilo)(heterociclilo), -C(O)(C₁₋₉ alquilo), -C(O)(C₂₋₆ alquenilo), -C(O)(C₂₋₆ alquinilo), -C(O)(C₃₋₁₅ cicloalquilo), -C(O)(C₁₋₈ haloalquilo), -C(O)(arilo), -C(O)(heteroarilo), -C(O)(heterociclilo), -C(O)O(C₁₋₉ alquilo), -C(O)O(C₂₋₆ alquenilo), -C(O)O(C₂₋₆ alquinilo), -C(O)O(C₃₋₁₅ cicloalquilo), -C(O)O(C₁₋₈ haloalquilo), -C(O)O(arilo), -C(O)O(heteroarilo), -C(O)O(heterociclilo), -C(O)NH₂, -C(O)NH(C₁₋₉ alquilo), -C(O)NH(C₂₋₆ alquenilo), -C(O)NH(C₂₋₆ alquinilo), -C(O)NH(C₃₋₁₅ cicloalquilo), -C(O)NH(C₁₋₈ haloalquilo), -C(O)NH(arilo), -C(O)NH(heteroarilo), -C(O)NH(heterociclilo), -C(O)N(C₁₋₉ alquilo)₂, -C(O)N(C₂₋₆ alquenilo)₂, -C(O)N(C₂₋₆ alquinilo)₂, -C(O)N(C₃₋₁₅ cicloalquilo)₂, -C(O)N(C₁₋₈ haloalquilo)₂, -C(O)N(arilo)₂, -C(O)N(heteroarilo)₂, -C(O)N(heterociclilo)₂, -NHC(O)(C₁₋₉ alquilo), -NHC(O)(C₂₋₆ alquenilo), -NHC(O)(C₂₋₆ alquinilo), -NHC(O)(C₃₋₁₅ cicloalquilo), -NHC(O)(C₁₋₈ haloalquilo), -NHC(O)(arilo), -NHC(O)(heteroarilo), -NHC(O)(heterociclilo), -NHC(O)O(C₁₋₉ alquilo), -NHC(O)O(C₂₋₆ alquenilo), -NHC(O)O(C₂₋₆ alquinilo), -NHC(O)O(C₃₋₁₅ cicloalquilo), -NHC(O)O(C₁₋₈ haloalquilo), -NHC(O)O(arilo), -NHC(O)O(heteroarilo), -NHC(O)O(heterociclilo), -NHC(O)NH(C₁₋₉ alquilo), -NHC(O)NH(C₂₋₆ alquenilo), -NHC(O)NH(C₂₋₆ alquinilo), -NHC(O)NH(C₃₋₁₅ cicloalquilo), -NHC(O)NH(C₁₋₈ haloalquilo), -NHC(O)NH(arilo), -NHC(O)NH(heteroarilo), -NHC(O)NH(heterociclilo), -SH, -S(C₁₋₉ alquilo), -S(C₂₋₆ alquenilo), -S(C₂₋₆ alquinilo), -S(C₃₋₁₅ cicloalquilo), -S(C₁₋₈ haloalquilo), -S(arilo), -S(heteroarilo), -S(heterociclilo), -NHS(O)(C₁₋₉ alquilo), -N(C₁₋₉ alquilo)S(O)(C₁₋₉ alquilo), -S(O)N(C₁₋₉ alquilo)₂, -S(O)(C₁₋₉ alquilo), -S(O)(NH)(C₁₋₉ alquilo), -S(O)(C₂₋₆ alquenilo), -S(O)(C₂₋₆ alquinilo), -S(O)(C₃₋₁₅ cicloalquilo), -S(O)(C₁₋₈ haloalquilo), -S(O)(arilo), -S(O)(heteroarilo), -S(O)(heterociclilo), -S(O)₂(C₁₋₉ alquilo), -S(O)₂(C₂₋₆ alquenilo), -S(O)₂(C₂₋₆ alquinilo), -S(O)₂(C₃₋₁₅ cicloalquilo), -S(O)₂(C₁₋₈ haloalquilo), -S(O)₂(arilo), -S(O)₂(heteroarilo), -S(O)₂(heterociclilo), -S(O)₂NH(C₁₋₉ alquilo), o -S(O)₂N(C₁₋₉ alquilo)₂; en donde cualquier alquilo, cicloalquilo, arilo, heteroarilo, o heterociclilo es opcionalmente sustituido con uno a cuatro halo, C₁₋₉ alquilo, C₁₋₈ haloalquilo, -OH, -NH₂, -NH(C₁₋₉ alquilo), -NH(C₃₋₁₅ cicloalquilo), -NH(C₁₋₈ haloalquilo), -NH(arilo), -NH(heteroarilo), -NH(heterociclilo), -N(C₁₋₉ alquilo)₂, -N(C₃₋₁₅ cicloalquilo)₂, -NHC(O)(C₃₋₁₅ cicloalquilo), -NHC(O)(C₁₋₈ haloalquilo), -NHC(O)(arilo), -NHC(O)(heteroarilo), -NHC(O)(heterociclilo), -NHC(O)O(C₁₋₉ alquilo), -NHC(O)O(C₂₋₆ alquinilo), -NHC(O)O(C₃₋₁₅ cicloalquilo), -NHC(O)O(C₁₋₈ haloalquilo), -NHC(O)O(arilo), -NHC(O)O(heteroarilo), -NHC(O)O(heterociclilo), -NHC(O)NH(C₁₋₉ alquilo), -S(O)(NH)(C₁₋₉ alquilo), -S(O)₂(C₁₋₉ alquilo), -S(O)₂(C₃₋₁₅ cicloalquilo), -S(O)₂(C₁₋₈ haloalquilo), -S(O)₂(arilo), -S(O)₂(heteroarilo), -S(O)₂(heterociclilo), -S(O)₂NH(C₁₋₉ alquilo), -S(O)₂N(C₁₋₉ alquilo)₂, -O(C₃₋₁₅ cicloalquilo), -O(C₁₋₈ haloalquilo), -O(arilo), -O(heteroarilo), -O(heterociclilo), o -O(C₁₋₉ alquilo); m es 0, 1, ó 2; o una sal farmacéuticamente aceptable, estereoisómero, mezcla de estereoisómeros, o análogo deuterado de los mismos.
ARP200101649A 2019-06-14 2020-06-11 Moduladores de cot y métodos de uso de los mismos AR119138A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962861390P 2019-06-14 2019-06-14

Publications (1)

Publication Number Publication Date
AR119138A1 true AR119138A1 (es) 2021-11-24

Family

ID=71950735

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP200101649A AR119138A1 (es) 2019-06-14 2020-06-11 Moduladores de cot y métodos de uso de los mismos

Country Status (30)

Country Link
US (7) US20210061831A1 (es)
EP (2) EP3983064B1 (es)
JP (4) JP7286813B2 (es)
KR (3) KR102714138B1 (es)
CN (3) CN117946167A (es)
AR (1) AR119138A1 (es)
AU (2) AU2020290461B2 (es)
BR (1) BR112021025039A2 (es)
CA (1) CA3142478A1 (es)
CL (2) CL2021003336A1 (es)
CO (1) CO2021016834A2 (es)
CR (1) CR20210620A (es)
DK (1) DK3983064T3 (es)
DO (1) DOP2023000172A (es)
ES (1) ES2978687T3 (es)
FI (1) FI3983064T3 (es)
HR (1) HRP20240351T1 (es)
HU (1) HUE066717T2 (es)
IL (4) IL299567B2 (es)
LT (1) LT3983064T (es)
MX (2) MX2021015545A (es)
PE (1) PE20220509A1 (es)
PH (1) PH12021553010A1 (es)
PL (1) PL3983064T3 (es)
PT (1) PT3983064T (es)
SG (1) SG11202113307TA (es)
SI (1) SI3983064T1 (es)
TW (2) TW202235416A (es)
UA (1) UA128242C2 (es)
WO (1) WO2020252151A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3456717B1 (en) 2015-07-06 2021-03-17 Gilead Sciences, Inc. 4,6-diamino-quinoline-3-carbonitrile derivative as cancer osaka thyroid (cot) modulator for treating inflammatory disease
TW202235416A (zh) 2019-06-14 2022-09-16 美商基利科學股份有限公司 Cot 調節劑及其使用方法
EP4126231A1 (en) 2020-03-30 2023-02-08 Gilead Sciences, Inc. Solid forms of (s)-6-(((1-(bicyclo[1.1.1]pentan-1-yl)-1h-1,2,3-triazol-4-yl)2-methyl-1-oxo-1,2- dihydroisoquinolin-5-yl)methyl)))amino)8-chloro-(neopentylamino)quinoline-3-carb onitrile a cot inhibitor compound
PL4126862T3 (pl) 2020-04-02 2025-09-08 Gilead Sciences, Inc. Sposób wytwarzania związku będącego inhibitorem cot
TW202304435A (zh) * 2021-06-04 2023-02-01 美商基利科學股份有限公司 治療ｎａｓｈ之方法
CA3223412A1 (en) * 2021-06-23 2022-12-29 Erika BUTLER Process for preparing egfr inhibitors
AU2023269038A1 (en) * 2022-05-12 2024-11-28 Gilead Sciences, Inc. Solid forms of a compound for modulating cot
WO2024182811A1 (en) * 2023-03-02 2024-09-06 University Of South Florida Compositions and methods for treating uterine leiomyomas
WO2024245157A1 (zh) * 2023-05-30 2024-12-05 浙江星浩澎博医药有限公司 氮杂喹啉环衍生物
TW202523303A (zh) 2023-12-11 2025-06-16 美商基利科學股份有限公司 用於治療發炎性腸道疾病之化合物及方法

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3930837A (en) 1971-12-31 1976-01-06 Ici Australia Limited 3-chloro-5-acetamidaisoquinoline as a herbicide
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4151298A (en) 1977-01-10 1979-04-24 Ciba-Geigy Corporation Anthelmintic compositions
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
JP2634438B2 (ja) 1988-07-26 1997-07-23 三井東圧化学株式会社 不斉ビスオキサゾリルピリジン誘導体およびその製造方法
DE4014171A1 (de) 1990-05-03 1991-11-07 Basf Ag Cyanochinolinverbindungen
GB9310700D0 (en) 1993-05-24 1993-07-07 Zeneca Ltd Novel composition
UA73073C2 (uk) 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
AU734678B2 (en) 1997-08-28 2001-06-21 Nissan Chemical Industries Ltd. Industrial antibacterial and antifungal agents, algicides and agents for preventing adhesion of organisms containing a cyanoacrylate compound
CA2336691C (en) 1998-07-10 2009-02-10 Massachusetts Institute Of Technology Ligands for metals and metal-catalyzed processes
JP4537582B2 (ja) 1998-09-29 2010-09-01 アメリカン・サイアナミド・カンパニー プロテインチロシンキナーゼインヒビターとしての置換３−シアノキノリン
RU2312857C2 (ru) 2002-03-20 2007-12-20 Бристол-Маерс Сквибб Компани Фосфатные производные фтороксиндолов и способ лечения с их использованием
RU2327689C2 (ru) 2003-03-03 2008-06-27 Ф.Хоффманн-Ля Рош Аг 2,5- замещенные тетрагидроизохинолины и фармацевтическая композиция для модуляции 5-нт6
SG145744A1 (en) 2003-08-19 2008-09-29 Wyeth Corp Process for the preparation of 4-amino-3- quinolinecarbonitriles
US7399865B2 (en) 2003-09-15 2008-07-15 Wyeth Protein tyrosine kinase enzyme inhibitors
TW200529846A (en) 2004-02-20 2005-09-16 Wyeth Corp 3-quinolinecarbonitrile protein kinase inhibitors
GB0420722D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
JP2008540656A (ja) 2005-05-18 2008-11-20 ワイス Ｔｐｌ２キナーゼの３−シアノキノリン阻害物質ならびにそれを製造および使用する方法
EP1881981A1 (en) 2005-05-18 2008-01-30 Wyeth 4, 6-diamino-[1,7] naphthyridine-3-carbonitrile inhibitors of tpl2 kinase and methods of making and using the same
TW200718687A (en) 2005-05-27 2007-05-16 Wyeth Corp Inhibitors of cytosolic phospholipase A2
CN102516176A (zh) 2005-10-28 2012-06-27 雅培制药有限公司 抑制trpv1受体的吲唑衍生物
MX2008012482A (es) 2006-03-31 2008-10-10 Abbott Lab Compuestos de indazol.
WO2008055950A1 (en) 2006-11-09 2008-05-15 Probiodrug Ag Novel inhibitors of glutaminyl cyclase
US8389544B2 (en) 2007-01-17 2013-03-05 The Hong Kong University Of Science And Technology Isoquinolone compounds as subtype-selective agonists for melatonin receptors MT1 and MT2
FR2919286A1 (fr) 2007-07-27 2009-01-30 Sanofi Aventis Sa Derives de derives de 1-oxo-1,2-dihydroisoquinoleine-5- carboxamides et de 4-oxo-3,4-dihydroquinazoline-8- carboxamides,leur preparation et leur application en therapeutique.
GB0820856D0 (en) 2008-11-14 2008-12-24 Univ Leuven Kath Novel inhibitors of flavivirus replication
TWI598347B (zh) 2009-07-13 2017-09-11 基利科學股份有限公司 調節細胞凋亡信號之激酶的抑制劑
GB0922302D0 (en) 2009-12-22 2010-02-03 Imp Innovations Ltd Compounds
US20130059851A1 (en) 2010-03-09 2013-03-07 Dana-Farber Cancer Institute, Inc. Methods of Diagnosing and Treating Cancer in Patients Having or Developing Resistance to a First Cancer Therapy
RU2600928C2 (ru) 2010-06-09 2016-10-27 Тяньцзинь Химэй Байо-Тек Ко., Лтд Цианохинолиновые производные
WO2012153796A1 (ja) 2011-05-10 2012-11-15 協和発酵キリン株式会社 ピリミドジアゼピノン化合物
US9173395B2 (en) 2011-07-04 2015-11-03 Bayer Intellectual Property Gmbh Use of substituted isoquinolinones, isoquinolindiones, isoquinolintriones and dihydroisoquinolinones or in each case salts thereof as active agents against abiotic stress in plants
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
PT2772482E (pt) 2011-10-27 2016-06-03 Taisho Pharmaceutical Co Ltd Derivados de azole
UA123760C2 (uk) 2011-11-11 2021-06-02 Гіліад Аполло, Ллс Сполука (варіанти) та композиція, що містить сполуку
UY34573A (es) 2012-01-27 2013-06-28 Gilead Sciences Inc Inhibidor de la quinasa que regula la señal de la apoptosis
CN103483363B (zh) 2012-06-13 2016-12-21 上海赛迦化工产品有限公司 多样性的手性氨基硼酸及其制备方法和应用
IN2015DN03795A (es) 2012-10-24 2015-10-02 Inserm Inst Nat De La Santé Et De La Rech Médicale
CN103408572B (zh) 2013-07-12 2015-12-02 上海工程技术大学 手性氨基硼酸衍生物及其制备方法和应用
WO2015070366A1 (en) 2013-11-12 2015-05-21 Merck Sharp & Dohme Corp. Aryl linked imidazole and triazole derivatives and methods of use thereof for improving the pharmacokinetics of a drug
CN108947867A (zh) 2013-12-12 2018-12-07 卡利拉制药公司 双环烷基化合物及合成
EP3114107B1 (en) 2014-03-07 2020-07-22 Recurium IP Holdings, LLC Propellane derivates and synthesis
EP3166938A4 (en) 2014-07-11 2018-01-17 Northwestern University 2-imidazolyl-pyrimidine scaffolds as potent and selective inhibitors of neuronal nitric oxide synthase
CA2961605C (en) 2014-09-17 2023-01-10 Kalyra Pharmaceuticals, Inc. Bicyclic compounds
BR112017005693A2 (pt) 2014-09-24 2017-12-12 Gilead Sciences Inc método para tratar e/ou prevenir uma doença hepática, e, composição farmacêutica.
BR112017013382A2 (pt) 2014-12-23 2018-02-14 Gilead Sciences Inc método para preparar um composto, composto, e, ácido.
MA41252A (fr) 2014-12-23 2017-10-31 Gilead Sciences Inc Formes solides d'un inhibiteur d'ask 1
JP2018501276A (ja) 2015-01-09 2018-01-18 ギリアド アポロ， エルエルシー 非アルコール性脂肪肝疾患の処置のためのａｃｃ阻害剤併用療法
KR20170102352A (ko) 2015-01-16 2017-09-08 쓰리엠 이노베이티브 프로퍼티즈 컴파니 그리드 결과를 개선하기 위해 그리드 액션을 선택하기 위한 시스템 및 방법
EP3456717B1 (en) 2015-07-06 2021-03-17 Gilead Sciences, Inc. 4,6-diamino-quinoline-3-carbonitrile derivative as cancer osaka thyroid (cot) modulator for treating inflammatory disease
US9815818B2 (en) * 2015-07-06 2017-11-14 Gilead Sciences, Inc. Cot modulators and methods of use thereof
EP3398598B1 (en) 2015-12-31 2022-04-06 Hitgen Inc. Sulfonamide derivative and preparation method and use thereof
CA3155220C (en) 2016-03-02 2024-01-16 Gilead Apollo, Llc Solid forms of a thienopyrimidinedione acc inhibitor and methods for production thereof
JP6738895B2 (ja) 2016-06-21 2020-08-12 Ｐｈｃホールディングス株式会社 カタラーゼ阻害剤及びカタラーゼ阻害剤を用いるアナライトの測定方法
EP3478674B1 (en) 2016-06-30 2020-05-13 Gilead Sciences, Inc. 4,6-diaminoquinazolines as cot modulators and methods of use thereof
CN106512014A (zh) 2016-10-27 2017-03-22 武汉大学 肿瘤进展位点2在治疗脂肪肝和ⅱ型糖尿病中的功能和应用
KR102485620B1 (ko) 2017-03-03 2023-01-09 길리애드 사이언시즈, 인코포레이티드 Acc 억제제 및 그의 고체 형태를 제조하는 방법
ES2927019T3 (es) 2017-03-28 2022-11-02 Gilead Sciences Inc Combinaciones terapéuticas para el tratamiento de enfermedades hepáticas
JP2020516627A (ja) 2017-04-12 2020-06-11 ギリアード サイエンシーズ， インコーポレイテッド 肝疾患を処置する方法
CA3077273A1 (en) 2017-10-06 2019-04-11 Gilead Sciences, Inc. Combination therapy comprising an acc inhibitor
CN108636625B (zh) * 2018-03-13 2021-09-14 因诺弥斯特有限责任公司 多模式流体喷嘴
JP2022519906A (ja) 2019-02-19 2022-03-25 ギリアード サイエンシーズ， インコーポレイテッド Ｆｘｒアゴニストの固体形態
CN109928956B (zh) 2019-02-27 2020-10-13 杭州偶联医药科技有限公司 一种靶向泛素化降解egfr蛋白的化合物及其药物组合物和应用
WO2020185685A1 (en) 2019-03-08 2020-09-17 The Regents Of The University Of California Compositions and methods for treating acne
TW202235416A (zh) 2019-06-14 2022-09-16 美商基利科學股份有限公司 Cot 調節劑及其使用方法
AR119594A1 (es) 2019-08-09 2021-12-29 Gilead Sciences Inc Derivados de tienopirimidina como inhibidores acc y usos de los mismos
EP4126231A1 (en) 2020-03-30 2023-02-08 Gilead Sciences, Inc. Solid forms of (s)-6-(((1-(bicyclo[1.1.1]pentan-1-yl)-1h-1,2,3-triazol-4-yl)2-methyl-1-oxo-1,2- dihydroisoquinolin-5-yl)methyl)))amino)8-chloro-(neopentylamino)quinoline-3-carb onitrile a cot inhibitor compound
PL4126862T3 (pl) 2020-04-02 2025-09-08 Gilead Sciences, Inc. Sposób wytwarzania związku będącego inhibitorem cot
CN112300072A (zh) 2020-10-14 2021-02-02 常州工学院 5-碘异喹啉类化合物的高收率合成方法
TW202304435A (zh) * 2021-06-04 2023-02-01 美商基利科學股份有限公司 治療ｎａｓｈ之方法
AU2023269038A1 (en) 2022-05-12 2024-11-28 Gilead Sciences, Inc. Solid forms of a compound for modulating cot

Also Published As

Publication number Publication date
US20220259234A1 (en) 2022-08-18
PL3983064T3 (pl) 2024-06-24
US20250333428A1 (en) 2025-10-30
AU2024202085B2 (en) 2025-12-04
JP7671796B2 (ja) 2025-05-02
CN114026104B (zh) 2024-01-30
JP2023076560A (ja) 2023-06-01
JP2022536758A (ja) 2022-08-18
CR20210620A (es) 2022-02-08
HUE066717T2 (hu) 2024-09-28
FI3983064T3 (fi) 2024-04-18
TW202112766A (zh) 2021-04-01
DOP2023000172A (es) 2023-09-29
IL299567B2 (en) 2024-08-01
IL311531A (en) 2024-05-01
LT3983064T (lt) 2024-06-10
US20240043458A1 (en) 2024-02-08
KR20220020904A (ko) 2022-02-21
US11325930B2 (en) 2022-05-10
US10947259B2 (en) 2021-03-16
KR102609360B1 (ko) 2023-12-05
JP2024166271A (ja) 2024-11-28
EP4375279A2 (en) 2024-05-29
KR102714138B1 (ko) 2024-10-11
AU2024202085A1 (en) 2024-04-18
CL2021003336A1 (es) 2022-08-19
PE20220509A1 (es) 2022-04-07
ES2978687T3 (es) 2024-09-17
NZ782835A (en) 2025-02-28
KR20240151860A (ko) 2024-10-18
CN117946167A (zh) 2024-04-30
US11827662B2 (en) 2023-11-28
AU2020290461B2 (en) 2024-01-04
PH12021553010A1 (en) 2022-11-07
US20210061831A1 (en) 2021-03-04
IL288310A (en) 2022-01-01
DK3983064T3 (da) 2024-03-18
CN117946166A (zh) 2024-04-30
EP3983064A1 (en) 2022-04-20
SG11202113307TA (en) 2021-12-30
TWI770527B (zh) 2022-07-11
CA3142478A1 (en) 2020-12-17
JP7286813B2 (ja) 2023-06-05
KR20230169422A (ko) 2023-12-15
AU2020290461A1 (en) 2021-12-23
US20220235078A1 (en) 2022-07-28
IL299567B1 (en) 2024-04-01
MX2021015545A (es) 2022-02-16
JP2025170010A (ja) 2025-11-14
UA128242C2 (uk) 2024-05-15
IL323450A (en) 2025-11-01
WO2020252151A1 (en) 2020-12-17
MX2025010745A (es) 2025-10-01
BR112021025039A2 (pt) 2022-04-26
CN114026104A (zh) 2022-02-08
CL2023000112A1 (es) 2023-08-25
CO2021016834A2 (es) 2022-01-17
US20200392170A1 (en) 2020-12-17
EP4375279A3 (en) 2024-08-21
JP7735505B2 (ja) 2025-09-08
SI3983064T1 (sl) 2024-05-31
PT3983064T (pt) 2024-05-07
TW202235416A (zh) 2022-09-16
HRP20240351T1 (hr) 2024-06-07
IL299567A (en) 2023-02-01
EP3983064B1 (en) 2024-03-06
US20210147454A1 (en) 2021-05-20
US12398160B2 (en) 2025-08-26

Similar Documents

Publication Publication Date Title
AR119138A1 (es) Moduladores de cot y métodos de uso de los mismos
AR108926A1 (es) Moduladores de cot y sus métodos de uso
AR118205A1 (es) Compuestos que tienen actividad inductora de ferroptosis
AR110935A1 (es) Derivados de pirrolo[1,2-b]piridazina
AR097008A1 (es) Derivados fosfatos, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
AR127404A1 (es) Inhibidores de la metionina adenosiltransferasa 2a (mat2a) y usos de los mismos
AR117139A1 (es) Derivados de piridooxazinona como inhibidores de monoacilglicerol ligasa (magl)
AR089774A1 (es) Derivados de indolizina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
AR092959A1 (es) Derivados de nucleosidos 2-metil sustituidos y metodos de uso de los mismos para el tratamiento de enfermedades virales
AR098906A1 (es) Derivados de tienopirimidina, un proceso para su preparación y composiciones farmacéuticas que los contienen
AR096979A1 (es) Derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
AR088029A1 (es) Compuestos de pirimidina sustituidos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento del dolor, accidentes cerebrovasculares, epilepsia y otras enfermedades del sistema nervioso central
AR104025A1 (es) Carbamatos de piperazina como moduladores de magl y/o abhd6, procesos para su preparación y composiciones farmacéuticas
AR088097A1 (es) Compuestos herbicidas
AR090293A1 (es) Inhibidores de quinasa a base de arileter
AR099913A1 (es) Derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
AR092347A1 (es) Derivados de azaindol
AR111271A1 (es) Inhibidores dobles de magl y faah
AR112907A1 (es) Pirazoles inhibidores de monoacilglicerol lipasa (magl)
AR100714A1 (es) Derivados de alquilo y arilo de compuestos de 1-oxa-4,9-diazaespiro undecano que tienen actividad multimodal contra el dolor
AR087563A1 (es) Compuestos de benzofurano para el tratamiento de infecciones por el virus de hepatitis c (hcv)
AR091034A1 (es) Derivados de estrigolactamas reguladores del crecimiento vegetal
AR116392A1 (es) Compuestos de fenoxi-piridil-pirimidina y métodos de uso
AR121573A1 (es) Moduladores de nlrp3
AR115906A1 (es) Derivados de haloalilamina sulfona como inhibidores de lisil oxidasas